Dr. Ghassan Abou-Alfa of Memorial Sloan Kettering Cancer Center shares a recent abstract from ASCO GI, IMBRAVE-151, A Phase II, randomized, double-blind placebo-controlled study of atezolizumab with or without bevacizumab in combination
By: Tiantian Zhang1, Yiqun Han2, Lei Deng3 1. Department of Internal Medicine, University of Central Florida, Pensacola, FL 2. Mayo Clinic, Rochester, MN 3. University of Washington/Fred Hutch Cancer Center, Seattle, WA
More
By: Zhiting Tang1, Lei Deng2 1. Unity Hospital, Rochester Regional Health, Rochester, NY2. University of Washington/Fred Hutch Cancer Center, Seattle, WA LAURA: A randomized, double-blind, Phase III study of chemoradiation followed
More
By Dr. Shipra Gandhi from Roswell Park Comprehensive Cancer Center Findings from the MonarchE clinical trial1 led to the approval of combination abemaciclib with AI in the adjuvant setting for patients
More
Dr. Ghassan Abou-Alfa of Memorial Sloan Kettering Cancer Center shares a recent abstract from ASCO GI, IMBRAVE-151, A Phase II, randomized, double-blind placebo-controlled study of atezolizumab with or without bevacizumab in combination
More
ASCO Direct™ Highlights Oncology conference held in Seattle to present and discuss the latest findings in cancer research and treatments The Binaytara Foundation held the ASCO Direct™ Highlights: 2022 Official Annual Meeting
More